CMV

COMMUNIQUÉS West-GlobeNewswire

BioSig Technologies, Inc. Appoints Mr. Anthony Amato to Position of Chief Executive Officer, Effective Immediately
30/04/2024
Mr. Amato will also serve on the Company’s Board of Directors Westport, CT, April 30, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) or (“BioSig” or "the Company"), a medical technology Company [...]
XORTX Reprices Warrants Issued in Connection with Previous Private Placements
30/04/2024
CALGARY, Alberta, April 30, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on [...]
Crossject annonce le lancement d’une augmentation de capital
30/04/2024
Crossject annonce le lancement d’une augmentation de capital avec maintien du droit préférentiel de souscription d’un montant d’environ 8 millions d’euros pour renforcer ses sources de financement de l’enregistrement de [...]
Synaptive Medical Showcases First Clinical Use of Near-Infrared Fluorescence Visualization on Robotic Exoscope at the American Association of Neurological Surgeons Annual Meeting
30/04/2024
Surgeons report that Modus X is the ultimate visualization tool for all levels of complex microsurgery Synaptive Medical will demonstrate its recent FDA cleared near-infrared fluorescence that is now available on its [...]
AB Science announces a slight delay in the publication of its 2023 annual financial report
30/04/2024
PRESS RELEASE AB SCIENCE ANNOUNCES A SLIGHT DELAY IN THE PUBLICATION OF ITS 2023 ANNUAL FINANCIAL REPORT THE COMPANY WILL PUBLISH ITS 2023 ANNUAL FINANCIAL REPORT NO LATER THAN 15 MAY 2024 Paris, April 30 2024, 6.30pm [...]
AB Science annonce un léger décalage de la publication de son rapport financier annuel 2023
30/04/2024
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE UN LEGER DECALAGE DE LA PUBLICATION DE SON RAPPORT FINANCIER ANNUEL 2023 LA SOCIETE PUBLIERA SON RAPPORT FINANCIER ANNUEL 2023 AU PLUS TARD LE 15 MAI 2024 Paris, 30 avril 2024, [...]
EssilorLuxottica: EssilorLuxottica 2024 Annual Shareholders’ Meeting, starting a new chapter of the Company’s history
30/04/2024
EssilorLuxottica 2024 Annual Shareholders’ Meeting, starting a new chapter of the Company’s history All resolutions proposed by the Board of Directors adopted Dividend of Euro 3.95 per share, with option for payment in [...]
EssilorLuxottica: Assemblée générale 2024 d’EssilorLuxottica, un nouveau chapitre de l’histoire du Groupe s’ouvre
30/04/2024
Assemblée générale 2024 d’EssilorLuxottica, un nouveau chapitre de l’histoire du Groupe s’ouvre Toutes les résolutions proposées par le Conseil d’administration adoptées Dividende de 3,95 € par action, avec possibilité [...]
Resolutions from the annual shareholders’ meeting 2024
30/04/2024
Today an ordinary shareholders’ meeting was conducted. The following resolutions were made : • Approval of the audited Annual Report for 2023 • Approval of distribution of profit with payment of an ordinary dividend of [...]
Press Release: Annual General Meeting of April 30, 2024
30/04/2024
Annual General Meeting of April 30, 2024 Approval of the financial statements for the fiscal year 2023 Distribution of a cash dividend of €3.76 per share, with payment as of May 15, 2024 Board composition: renewal of [...]
Communiqué de presse : Assemblée Générale Annuelle du 30 avril 2024
30/04/2024
Assemblée Générale Annuelle du 30 avril 2024 Approbation des comptes sociaux et des comptes consolidés de l’exercice 2023 Distribution d’un dividende en numéraire de 3,76 euros par action, dont la mise en paiement [...]
Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting
30/04/2024
April 30, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious [...]
You:Flourish Unveils Revolutionary Wellness Platform, Transforming LGBTQ+ Access to Support and Care in Colorado and Beyond
30/04/2024
Coloradans will be the first beneficiaries, gaining access to a directory of vetted and affirming mental health professionals, peer networking opportunities, and a wealth of wellness resources DENVER, April 30, 2024 ( [...]
Medicenna Therapeutics Announces Closing of CA$20 Million Investment from RA Capital Management
30/04/2024
Not for distribution to United States news wire services or for dissemination in the United States TORONTO and HOUSTON, April 30, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX [...]
Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics
30/04/2024
LOS ANGELES and AMSTERDAM, April 30, 2024 (GLOBE NEWSWIRE) -- RenovaroCube, wholly owned subsidiary of Renovaro, Inc. (Nasdaq: RENB), a company at the forefront of AI-driven healthcare innovation, proudly unveils [...]
Biocodex Microbiota Foundation Invites Canadian Academics and Scientists to Apply for €25,000 Research Grant to Advance Microbiota’s role Study in health and diseases
30/04/2024
MONTREAL, April 30, 2024 (GLOBE NEWSWIRE) -- The Biocodex Microbiota Foundation , an organization founded by Biocodex and dedicated to inspiring scientific projects that explore the microbiome, is calling for grant [...]
RS BioTherapeutics Launches Crowdfunding Campaign Through StartEngine
30/04/2024
CUMBERLAND, Md., April 30, 2024 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from diseases characterized by pulmonary inflammation, [...]
Resolutions of Annual Geneal Meeting
30/04/2024
April 30, 2024 Announcement no. 10 Resolutions of Annual Geneal Meeting COPENHAGEN, DENMARK and BOSTON, MA, USA, April 30, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro [...]
ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
30/04/2024
CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat dose PK/PD study of [...]

Pages